Why the study?
Does the frequency of microembolic signals correlate with antiplatelet therapy efficacy in patients with recent symptomatic carotid-artery stenosis?
Does the frequency of microembolic signals correlate with antiplatelet therapy efficacy in patients with recent symptomatic carotid-artery stenosis?
In patients with recent symptomatic carotid-artery stenosis, detecting more than one microembolic signal on TCD is associated with low response to antiplatelet therapy.
May identify low antiplatelet responders via TCD in carotid stenosis; leaves open prospective validation before clinical adoption.
BACKGROUND AND PURPOSE: The detection of microembolic signals in transcranial-Doppler monitoring is associated with a higher stroke risk. We investigated the correlation between the frequency of microembolic signals and the efficacy of the antiplatelet therapy in patients with a recent symptomatic carotid-artery stenosis. SUBJECTS AND METHODS: Thirty-two patients (mean age: 70 years, 22 men) with a recent symptomatic carotid-artery stenosis underwent 30-minute TCD-monitoring. Twenty-three patients received acetylsalicylic-acid and 9 patients clopidogrel as antiplatelet-therapy. At the same day, the antiplatelet effect was measured with multiple-electrode-impedance aggregometry. RESULTS: In 20 cases, the qualifying event was a stroke and in 12 cases, a TIA. Twenty-six of the patients had a >50% degree of stenosis. More than one microembolic signals were detected in 13 (40.6%) of the subjects, while multiple-electrode-impedance aggregometry revealed eight low responders (6 acetylsalicylic-acid, 2 clopidogrel). More than one microembolic signals were detected in 6 of the 8 (75.0%) patients with low response, but in only 7 of the 24 subjects (29.2%) with an effective antiplatelet treatment (sensitivity 75%, specificity 70.8%; Fisher's exact test: P = .038). CONCLUSIONS: Our study suggests that in patients with recent symptomatic carotid-artery stenosis the detection of more than one microembolic signals might serve as a useful marker for the effectiveness of the antiplatelet treatment.
No takes yet. Share an insight, caveat, or question.
Kerasnoudis et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: